This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Experts
Simani Price
Associate Vice President
Contact
SimaniPrice@xfmlsp.comOverview
Simani Price, PhD, an Associate Vice President for Public Health, directs multimethod evaluations, national surveys, and formative research that informs measures development, health interventions, and messaging. Her research and evaluation studies include public health topics such as birth defects, chronic disease, emergency preparedness, environmental health, immunization, tobacco, vaccine safety surveillance, and Zika.
Education
- PhD, Applied Social Psychology (minor in Marketing Research), Virginia Polytechnic Institute and State University
- MS, Experimental Psychology, Virginia Polytechnic Institute and State University
- MPA, Public Policy/Public Administration, University of Kentucky
- BA, Psychology and Political Science (Honors Program), University of Kentucky
-
Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry
European Urology
January 2023
F. Chen, R.K. Madduri, A.A. Rodriguez, B.F. Darst, A. Chou, X. Sheng, A. Wang, et al.
DOILink for: Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry -
Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods
6,
JAMA Network Open
January 2023
R. Link-Gelles, M.E. Levy, K. Natarajan, S.E. Reese, A.L. Naleway, S.J. Grannis, N.P. Klein, et al.
DOILink for: Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods -
Use of US blood donors for national serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 antibodies: Basis for an expanded national donor serosurveillance program
74,
Clinical Infectious Diseases
January 2022
M. Stone, C. Di Germanio, D.J. Wright, H. Sulaeman, H. Dave, Rebecca Fink, E.P. Notari, et al.
DOILink for: Use of US blood donors for national serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 antibodies: Basis for an expanded national donor serosurveillance program